Table 1 Comparison of PEA3 expression with clinicopathological parameters and growth factor markers
From: A positive role for PEA3 in HER2-mediated breast tumour progression
| Â | Total | PEA3-positive (%) | PEA3-negative (%) | P -value |
|---|---|---|---|---|
No. of patients | 107 | 50 (47%) | 57 (53%) | — |
Mean age | Â | 47.94 | 51.90 | 0.0776 |
Tumour size (mm) | Â | 3.17 | 2.72 | 0.0198 |
Grade | ||||
 Grade 3 | 55 | 37 (67%) | 18 (33%) |  |
 Non-grade 3 | 52 | 13 (25%) | 39 (75%) | <0.0001 |
Axillary lymph node status | ||||
 Node-positive | 69 | 38 (55%) | 31 (45%) |  |
 Node-negative | 38 | 12 (32%) | 26 (68%) | 0.0260 |
ER status | ||||
 Positive | 84 | 40 (48%) | 44 (52%) |  |
 Negative | 23 | 10 (43%) | 13 (57% | 0.8154 |
HER2 status | ||||
 Positive | 32 | 20 (63%) | 12 (37%) |  |
 Negative | 75 | 30 (40%) | 45 (60%) | 0.0369 |
Recurrence | ||||
 Positive | 23 | 20 (87%) | 3 (13%) |  |
 Negative | 84 | 30 (36%) | 54 (64%) | <0.0001 |
Phospho-raf | ||||
 Positive | 37 | 31 (84%) | 6 (16%) | <0.0001 |
 Negative | 70 | 19 (27%) | 51 (73%) |  |
